This week in Drug Discovery (6 – 10 October)
News round-up for 6 – 10 October by Bruno Quinney, Content Team at DDW.
In the week that the recipients of the Nobel Prizes are being announced, the prize for Physiology or Medicine has been given to three scientists for their discovery on regulatory T cells. Elsewhere, AI use continues to rise in pharma and biotech, while CAR-T therapy has been used for the first time to treat ulcerative colitis.
The top stories:
Nobel prize awarded for regulatory T cells discovery
The Nobel Assembly at Karolinska Institutet has decided to award the 2025 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning peripheral immune tolerance”.
Survey says AI leads investment, but lack of skills a barrier
The use of artificial intelligence (AI) continues to rise, according to the results of the Pistoia Alliance’s annual Lab of the Future survey.
First use of CAR-T therapy to treat ulcerative colitis
A team of physicians at the German Center for Immunotherapy has succeeded for the first time in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells.
FDA clears gene therapy trial in geographic atrophy
The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.
Lawrence Welch, Nuclera, confirmed to speak at DDW Symposium
DDW is delighted to welcome Lawrence Welch, Inside Sales Specialist at Nuclera, to the expert speaker line-up.
